213 related articles for article (PubMed ID: 23815163)
1. Gold(III) complexes of pyridyl- and isoquinolylamido ligands: structural, spectroscopic, and biological studies of a new class of dual topoisomerase I and II inhibitors.
Wilson CR; Fagenson AM; Ruangpradit W; Muller MT; Munro OQ
Inorg Chem; 2013 Jul; 52(14):7889-906. PubMed ID: 23815163
[TBL] [Abstract][Full Text] [Related]
2. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure.
Sun RW; Li CK; Ma DL; Yan JJ; Lok CN; Leung CH; Zhu N; Che CM
Chemistry; 2010 Mar; 16(10):3097-113. PubMed ID: 20162647
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human DNA topoisomerase IB by a cyclometalated gold III compound: analysis on the different steps of the enzyme catalytic cycle.
Castelli S; Vassallo O; Katkar P; Che CM; Sun RW; Desideri A
Arch Biochem Biophys; 2011 Dec; 516(2):108-12. PubMed ID: 22033340
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
5. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterisation and biological properties of gold(III) compounds with modified bipyridine and bipyridylamine ligands.
Casini A; Diawara MC; Scopelliti R; Zakeeruddin SM; Grätzel M; Dyson PJ
Dalton Trans; 2010 Mar; 39(9):2239-45. PubMed ID: 20162197
[TBL] [Abstract][Full Text] [Related]
7. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
9. Anticancer cyclometalated [Au(III)m(C(wedge)N(wedge)C)mL]n+ compounds: Synthesis and cytotoxic properties.
Li CK; Sun RW; Kui SC; Zhu N; Che CM
Chemistry; 2006 Jul; 12(20):5253-66. PubMed ID: 16642532
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2'-pyridyl)benzimidazole as ligand: comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives.
Serratrice M; Cinellu MA; Maiore L; Pilo M; Zucca A; Gabbiani C; Guerri A; Landini I; Nobili S; Mini E; Messori L
Inorg Chem; 2012 Mar; 51(5):3161-71. PubMed ID: 22339487
[TBL] [Abstract][Full Text] [Related]
11. Tumor cytotoxicity of 5,6-dimethyl-1,10-phenanthroline and its corresponding gold(III) complex.
Wein AN; Stockhausen AT; Hardcastle KI; Saadein MR; Peng SB; Wang D; Shin DM; Chen ZG; Eichler JF
J Inorg Biochem; 2011 May; 105(5):663-8. PubMed ID: 21450269
[TBL] [Abstract][Full Text] [Related]
12. Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Karki R; Thapa P; Yoo HY; Kadayat TM; Park PH; Na Y; Lee E; Jeon KH; Cho WJ; Choi H; Kwon Y; Lee ES
Eur J Med Chem; 2012 Mar; 49():219-28. PubMed ID: 22318164
[TBL] [Abstract][Full Text] [Related]
13. Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action.
Gouvea LR; Garcia LS; Lachter DR; Nunes PR; de Castro Pereira F; Silveira-Lacerda EP; Louro SR; Barbeira PJ; Teixeira LR
Eur J Med Chem; 2012 Sep; 55():67-73. PubMed ID: 22835721
[TBL] [Abstract][Full Text] [Related]
14. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
[TBL] [Abstract][Full Text] [Related]
15. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.
Ioanoviciu A; Antony S; Pommier Y; Staker BL; Stewart L; Cushman M
J Med Chem; 2005 Jul; 48(15):4803-14. PubMed ID: 16033260
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, anticancer evaluation and molecular docking studies of new heterocycles linked to sulfonamide moiety as novel human topoisomerase types I and II poisons.
Halawa AH; Elgammal WE; Hassan SM; Hassan AH; Nassar HS; Ebrahim HY; Mehany ABM; El-Agrody AM
Bioorg Chem; 2020 May; 98():103725. PubMed ID: 32199303
[TBL] [Abstract][Full Text] [Related]
19. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
